SeraCare Life Sciences Inc., which is traded on the Nasdaq, is potentially looking for a buyer, Reuters reported. The company recently received a proposal from MSMB Capital and is reportedly reviewing the possible deal, as well as other options. Lazard is advising SeraCare.
(Reuters) – SeraCare Life Sciences Inc said it is exploring strategic alternatives, including a possible sale of the company.
On June 23, it had received a buyout proposal from MSMB Capital for $4.25 a share and the company said the proposal would be reviewed in due course.
Lazard is advising SeraCare, whose portfolio includes diagnostic control product for HIV, plasma-derived reagents and contract research services.
Last week, the company said its Chief Executive resigned and announced third-quarter results below Wall Street estimates.
SeraCare shares closed at $3.79 on Friday on Nasdaq. (Reporting by Shravya Jain in Bangalore; Editing by Gopakumar Warrier)